Geometry Dash APK Hill Climb Racing APK
70.1 F
New York
Sunday, June 13, 2021

CytoDyn Inc (OTCMKTS:CYDY) Hits 4-Month High As Covid-19 Fear Grows

Must read

Bombardier, Inc. (OTCMKTS:BDRBF) Continues to Gain Momentum and Strength

Many stocks have managed to record significant gains in recent months and one that often flies under the radar is Bombardier,...

Grayscale Bitcoin Trust (Btc) (GBTC) Makes Big Move As Bitcoin Goes Wild

Bitcoin, the world’s biggest cryptocurrency by market cap, has been in the middle of a remarkable rally for the past few months...

Voyager Digital Ltd (OTCMKTS:VYGVF) Hits All-Time High on Download News

The remarkable rally enjoyed by several crypto assets over the course of the past months has also resulted in an increased demand...

Solar Integrated Roofing Corp (OTCMKTS:SIRC) Surges Higher On Sector Strength

The Solar Integrated Roofing Corp (OTCMKTS:SIRC) stock has come into sharp focus among investors and on Wednesday, the stock made significant gains...

The coronavirus pandemic unleashed chaos all over the world and also in the markets, however, some biotech companies working on treatments for coronavirus patients saw their stocks soar.

One such company is CytoDyn Inc (OTCMKTS:CYDY), which has been working on its product leronlimab that is meant for the treatment of such patients.

Recent Developments

On Monday, CytoDyn Inc (OTCMKTS:CYDY) went on an impressive rally and soared by as much as 20% on the back of a significant announcement from the company last week. It hit its highest level in four months and took its gains over the course of the past three weeks to 155%.

Back on December 17, the company announced that it completed its enrolment for the Phase 3 registrational study with regards to the possibility of using leronlimab as a treatment for patients with severe to critical COVID 19 symptoms. It goes without saying that it is a significant milestone for CytoDyn and the excitement among investors is understandable.

In total, the company has enrolled as many as 390 patients for this study and the data is going to be analyzed by experts over a period of 28 days. It has also been revealed that the results of the study are going to be released by CytoDyn at some point in the middle of January in 2021.

CytoDyn Inc (OTCMKTS:CYDY) has been one of the better performers this year so far and has recorded gains of as much as 246%. It is a highly impressive performance considering the fact that the wider industry grew by only 2.5% so far in 2020.

Earlier in October this year, CytoDyn continued to work on the study with the goal of hitting the primary endpoint after a review and recommendation from the DSMC (Data Safety Monitoring Committee). The DSMC provided its recommendation after going through the data related to 195 patients.

Disclosure: We hold no position in CYDY stock.

Latest article

American Diversified Holdings Corp (OTCMKTS:ADHC) Nears Critical Level

When a stock records significant gains and then crashes and repeats over the course of a few months, then it might be...

Reconnaissance Energy Africa Ltd (OTCMKTS:RECAF) Gathers Further Momentum

If you are currently looking for stocks that may have recorded massive gains within a short period of time, then it might...

Is Tilray Inc (NASDAQ:TLRY) Stock a Good Buy After The Recent Fall?

The cannabis sector may have had a hard time not too long ago but over the course of the past months, the...

Sysorex Inc (OTCMKTS:SYSX) Stock Still Riding Big News

Investors are always drawn to stocks that make a big jump out of nowhere. So it's no surprise that Sysorex Inc (OTCMKTS:SYSX)...

BIGG Digital Assets Inc (OTCMKTS:BBKCF) is Struggling to Regain Momentum

Over the course of the past few months, the continued rally in some of the biggest cryptocurrencies has led to considerable interest...
Şehirler arası nakliyat ve Şehirler arası taşımacılık konusunda en uygun fiyatlar ve en kaliteli hizmet.
ofis taşıma firmaları ve ofis taşıma konusunda en uygun fiyatlar ve en kaliteli hizmet. Affordable best sms verification service